IL6 and schizophrenia: On the other hand, RIS, a second generation atypical antipsychotic, which is prescribed for the treatment of schizophrenia, schizoaffective disorders, bipolar disorders, and behavioral irritability in autistic patients, was used to improve the situation given that the anti-inflammatory activity of RIS is mediated through the reduction of TNF-α, INF-γ, and IL-6 (Al-Amin et al., 2013; MacDowell et al., 2013; Ajami et al., 2014), and prevention of microglial activation (Zhu et al., 2014b).